PHVS Pharvaris NV

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2023 Annual Scientific Meeting, to be held from November 9-13, 2023, at the Anaheim Convention Center in Anaheim, CA.

Presentation details:

• Title: Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks’ manifestationsPresenter: Marc A. Riedl, M.D., M.S. Date/Time: Friday, November 10, 5:15-5:30 p.m. PST (8:15-8:30 p.m. EST)
• Title: Reasons not to treat HAE attacks and satisfaction for on-demand treatmentPresenter: Joan Mendivil, M.D. Date/Time: Saturday, November 11, 12:20-12:35 p.m. PST (3:20-3:35 p.m. EST)

On November 9 at 8:30 a.m. PST (11:30 a.m. EST), the ePosters and accompanying audio voice-overs will be made available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

About PharvarisBuilding on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
Maggie.beller@pharvaris.com